BioSpace News Archive

INVO Bioscience, Inc. (OTCQB: INVO), (“the Company”) a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell ® , the world’s only in vivo Intravaginal Culture System, announced that the company will trade under the symbol “INVO” effective at the beginning o

Bendit Technologies, an industry leader in the development of steerable microcatheters, announced that Richard Cappetta has been appointed as its Chairman of the Board.

TrueLimb Is an Ultralight, Comfortable, and Affordable Next-Generation Device Available Through an Industry-First Remote Process

Survey results point to people being more cautious with routine, leisure activities - such as traveling, brushing teeth, even playing with grandchildren - due to potential risk of major bleeding

Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor (“CGM”), together with BEAT®diabetes, a planned health subscription service designed to help people with Type 2 diabetes and prediabetes through person

Praxis Bioresearch, a biopharmaceutical company focused on the discovery and development of novel therapeutics for chronic central nervous system disorders, today announced that it has been issued a new patent (US Patent 10,662,146) by the United States Patent and Trademark Office covering pharmaceutical compositions comprising fencamfamine prodrug derivatives. The patent will remain in effect until September 13, 2036. Separately, the compa

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the receipt of a Notice of

Two top Bayer Consumer Health executives are taking on new responsibilities due to strategic moves the business is making in its executive team to strengthen its position as a leader in consumer healthcare in the North America region.

Gilead to Acquire 49.9% Equity Interest in Pionyr and Exclusive Option for $275 Million – – Gilead to Provide Funding for Pionyr’s Clinical Programs and Will Have the Right to Acquire Remainder of Pionyr for a $315 Million Option Exercise Fee – – Pionyr Eligible to Receive up to $1.15 Billion in Future Milestone Payments Upon Achievement of Certain Development and Regulatory Milestones – FOSTER CITY, Calif. & SOUTH SAN FRANC

LabLynx, Inc. today announced an important new component in its overall COVIDLiMS informatics solution for laboratories, designed to offer faster, more accurate coronavirus testing as well as ongoing risk management for businesses and organizations.